A Very Early Indicator That Bio Markets Could Be Nearing Inflection
Insights - There are early signs that private money in biotech is being accumulated but sitting on the sidelines waiting to be deployed. Q1 2023 was the … Continue Reading
Read NowInsights
Day One (DAWN) Sliding On Concerns of Competitoin and Trial Changes
Insights - In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDAapproval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the most … Continue Reading
Premium: Read Now
Lack of Clarity Continues Pushing Affimed Lower
Insights - Affimed announced a rather disappointing update yesterday. There was not much clarity shared and it seemed like AFM24 was seeing more data delays. The main … Continue Reading
Premium: Read Now
Karuna Latest Phase 3 Data Strengthens Upcoming NDA
Insights - Yesterday Karuna (KRTX) reported data on the third positive registrational trial, announcing that the trial met its primary endpoint. With three positive registrational trials reported … Continue Reading
Premium: Read Now
Government Steps In To Save Depositors, Many Bio Companies
Insights - The wild weekend was followed by an eventful Monday, especially for the biotech world. The SVB fiasco saw a solution that was a relief for … Continue Reading
Read Now
Silicon Valley Bank (SVB) Collpase Impacts Bio Markets
Insights - Silicon Valley Bank’s collapse has caused a ripple amongst the biotech world as the bank did business with about half of American tech and biotech … Continue Reading
Premium: Read NowDay One (DAWN) To Present Updated Results Ahead of NDA Submission
Insights - Day One’s Drug Ready for NDADay One Pharma (DAWN) is developing tovorafenib (DAY101), an oral pan-RAF inhibitor for pediatric low-grade gliomas (pLGG). Despite being the … Continue Reading
Premium: Read Now